Supernus Pharmaceuticals

SUPN

Market cap $2.76B

UNFI, TDOC, SUPN and BRP shine with strong relative price strength, earnings momentum, and analyst upgrades amid volatile markets.

Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Supernus Pharmaceuticals shares have rallied nicely after strong 2Q25 results, driven by robust Qelbree and Gocovri sales and a surge in Zurzuvae revenue. Supernus' recent acquisition of Sage Therapeutics added Zurzuvae, the only FDA-approved oral postpartum depression drug, and bolstered the company's balance sheet. Management raised FY25 revenue guidance by 11% and expects continued growth, with analysts forecasting solid EPS and sales through FY27.

ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today management will participate in the following September investor conferences: Cantor Global Healthcare Conference Date:Fireside chat:Place:     Wednesday, September 3, 2025 8:00 a.m.

While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.36 per share a year ago.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Jack A. Khattar - Founder, President, CEO, Secretary & Director Timothy C.